- ICH GCP
- US Clinical Trials Registry
- Klinisk forsøg NCT07639684
Impact of Endoscopic Sleeve Gastroplasty (ESG) in Obese Adults With Type 2 Diabetes (T2D) (MEASURE)
Metabolic Effects of Endoscopic Sleeve Gastroplasty in Obese Adults With Type 2 Diabetes: Evaluation of Glycemic Control, Insulin Use and Obesity Response
The goal of this clinical trial is to determine whether Endoscopic Sleeve Gastroplasty (ESG)-induced weight loss can improve glycemic outcomes and alter the trajectory toward insulin dependence in adults with obesity and inadequately controlled Type 2 Diabetes (T2D) despite guideline-directed therapy, including Glucagon-Like Peptide-1 Receptor Agonists (GLP-1RA)-based agents.
Studieoversigt
Status
Betingelser
Intervention / Behandling
Undersøgelsestype
Tilmelding (Anslået)
Fase
- Ikke anvendelig
Kontakter og lokationer
Studiekontakt
- Navn: Bridget Stanford
- Telefonnummer: 781-305-0506
- E-mail: bridget.stanford@bsci.com
Deltagelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
Tager imod sunde frivillige
Køn, der er berettiget til at studere
Beskrivelse
Inclusion Criteria:
- Willing and able to provide written informed consent to participate in the study
- Age ≥ 22 years
- BMI 30 - 50 kg/m2
- HbA1c 7.5 - 10.5%
- Type 2 Diabetes treated with incretin-based medication (aka GLP-1RA agonist or GLP-1RA/GIP dual agonist) at a stable, maximal tolerated dose for a minimum of 6 months +/- any other oral glucose lowering medications AND intention to initiate insulin therapy for glycemic management
- Stable weight (< 5% TBW) within the 3 months prior to screening
- Meets the indications for ESG procedure with OverStitch™ or OverStitch NXT™ Endoscopic Suturing System, excluding the following but not limited to the following: large hiatal hernia, potential bleeding gastric lesions (e.g. ulcers; erosive gastritis; varices; or vascular malformation), coagulopathy and antiplatelet/anticoagulant therapy that cannot be corrected
- Declines or is ineligible for metabolic bariatric surgery
- Agrees to abstain from taking any weight loss treatments or supplements that are not part of the lifestyle modification program for a year following the ESG procedure
- Willing and able to comply with the study procedure with standard of care lifestyle modification program and visit schedule.
Exclusion Criteria:
- Diabetes management with insulin. Prior use of insulin for gestational diabetes or short-term use (up to 1 month) in conjunction with an acute condition is acceptable.
- Noncompliance with medication regime for diabetic management
- More than one episode of clinically significant reactive or severe hypoglycemia within the prior 1 year. Reactive hypoglycemia is defined as postprandial hypoglycemia meeting Whipple's Triad; severe hypoglycemia is defined as any hypoglycemic episode requiring assistance from another person to administer carbohydrates, glucagon, or other corrective/resuscitative action
- History of ketoacidosis or hyperosmolar nonketotic coma within the past 1 year
- Has a contraindication for ESG procedure with OverStitch™ or OverStitch NXT™ Endoscopic Suturing System, including but not limited to the following: large hiatal hernia, potential bleeding gastric lesions (e.g. ulcers; erosive gastritis, varices, or vascular malformation), coagulopathy and antiplatelet/anticoagulant therapy that cannot be correct
- Prior gastric surgery, including but not limited to LSG or RYGP
- Any known conditions that impact weight loss or glycemic management
- Chronic systemic steroids or immunosuppressants taken at the time of enrollment or likely required during the study follow-up
- CKD stage 3+, defined as eGFR < 60 mL/min
- Persistent anemia, defined as hemoglobin < 10 g/dL
- Excessive alcohol consumption, defined as meeting or exceeding sex-based heavy drinking limits
- Use within the last three months prior to screening of over the counter or prescribed weight loss supplements / medications, or intent to use any weight loss medications or supplements during the study duration.
- The investigator's medical judgment that the subject is not a candidate for the ESG procedure due to findings, including but not limited to psychological and nutritional evaluation results obtained in the prior 12 months.
- Current pregnancy confirmed by site standard of care or planned pregnancy or breastfeeding for a year following the ESG procedure.
- Vulnerable subject.
- Current or planned participation in another clinical study.
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Behandling
- Tildeling: N/A
- Interventionel model: Enkelt gruppeopgave
- Maskning: Ingen (Åben etiket)
Våben og indgreb
Deltagergruppe / Arm |
Intervention / Behandling |
|---|---|
|
Eksperimentel: Endoscopic Sleeve Gastroplasty (ESG) Procedure
|
Endoscopic Sleeve Gastroplasty (ESG) with OverStitch Endoscopic Suturing System. |
Hvad måler undersøgelsen?
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Serious Adverse Events
Tidsramme: Through study completion, 12 months post procedure
|
Serious Adverse Events related to the study procedure and/or study device defined as Grade III or greater according to Clavien-Dindo Classification |
Through study completion, 12 months post procedure
|
|
Average Change in HbA1c
Tidsramme: 12 months post procedure
|
Mean change in HbA1c from baseline to 1-year. If rescue treatment is initiated, the last HbA1c value before initiation of rescue treatment is used for assessment of the primary effectiveness endpoint. |
12 months post procedure
|
Sekundære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Proportion of Subjects Achieving HbA1c < 7%
Tidsramme: 12 months post procedure
|
Proportion of subjects achieving HbA1c < 7% without initiating rescue treatment at 1-year |
12 months post procedure
|
Andre resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Weight Loss
Tidsramme: 1, 3, 6, 9, and 12 months post procedure
|
Total Body Weight Loss (TBWL) % and Excess Weight Loss (EWL) % at each visit |
1, 3, 6, 9, and 12 months post procedure
|
|
Proportion of Subjects with a Total Body Weight Loss ≥ 10%
Tidsramme: 1, 3, 6, 9, and 12 months post procedure
|
Proportion of subjects with a TBWL ≥ 10% at each visit |
1, 3, 6, 9, and 12 months post procedure
|
|
Proportion of Subjects Achieving HbA1c < 6.5%
Tidsramme: 12 months post procedure
|
Proportion of subjects achieving HbA1c < 6.5% without initiating rescue treatment at 1-year |
12 months post procedure
|
|
Proportion of Subjects Achieving TBWL ≥ 10% AND HbA1c < 6.5%
Tidsramme: 12 months post procedure
|
Proportion of subjects with a TBWL ≥ 10% AND a HbA1c < 6.5% without initiating rescue treatment at 1-year |
12 months post procedure
|
|
Proportion of Subjects Initiating Rescue Treatment
Tidsramme: Through study completion, 12 months post procedure
|
Proportion of subjects initiating rescue treatment at any time during the study follow-up period |
Through study completion, 12 months post procedure
|
|
Proportion of Subjects Meeting Rescue Criteria
Tidsramme: Through study completion, 12 months post procedure
|
Proportion of subjects meeting rescue criteria at any time during the study follow-up period |
Through study completion, 12 months post procedure
|
|
Proportion of Subjects with Improvement in Comorbidities
Tidsramme: 12 months post procedure
|
Proportion of subjects with improvement in each specific obesity-related comorbidity, as applicable, from baseline to 1-year: Hypertension, Dyslipidemia, Obstructive sleep apnea, Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) |
12 months post procedure
|
|
Change in Vitals
Tidsramme: 6 and 12 months post procedure
|
Change in vitals from baseline to 6-months and from baseline to 1-year: Systolic blood pressure, Diastolic blood pressure |
6 and 12 months post procedure
|
|
Change in Blood Laboratory Tests
Tidsramme: 6 and 12 months post procedure
|
Change in blood laboratory tests from baseline to 6-months and from baseline to 1-year: fasting plasma glucose, estimated glomerular filtration rate (eGFR), aspartate aminotransferase (AST), alanine aminotransferase (ALT,) low-density lipoprotein cholesterol (LDL-C), Triglycerides |
6 and 12 months post procedure
|
|
Change in Homeostatic Model Assessment for Insulin Resistance (HOMA-IR)
Tidsramme: 6 and 12 months post procedure
|
Change in HOMA-IR from baseline to 6-months and from baseline to 1-year |
6 and 12 months post procedure
|
|
Change in Fibrosis-4 (FIB-4)
Tidsramme: 6 and 12 months post procedure
|
Change in FIB-4 from baseline to 6-months and from baseline to 1-year |
6 and 12 months post procedure
|
|
Change in Nonalcoholic Fatty Liver Disease (NAFLD) Fibrosis Score
Tidsramme: 6 and 12 months post procedure
|
Change in NAFLD Fibrosis Score (NFS) from baseline to 6-months and from baseline to 1-year |
6 and 12 months post procedure
|
|
Change in Diabetes Treatment Satisfaction
Tidsramme: 12 months post procedure
|
Change in diabetes treatment satisfaction, as assessed by Diabetes Treatment Satisfaction Questionnaire - status (DTSQs), from baseline to 1-year and Diabetes Treatment Satisfaction Questionnaire - change (DTSQc) at 1-year; Positive score indicates an improvement in satisfaction, or a reduction in the frequency of hyper/hypoglycemia. Negative score indicates a deterioration in satisfaction, or an increase in the frequency of hyper/hypoglycemia. Zero indicates no change in satisfaction or symptoms. |
12 months post procedure
|
|
Change in Diabetes Self-Care Activity
Tidsramme: 6 and 12 months post procedure
|
Change in diabetes self-care activity, as assessed by Summary of Diabetes Self-Care Activity (SDSCA), from baseline to 6-months and from baseline to 1-year; Higher scores indicate better compliance with diabetic self-care recommendations. Lower scores point to areas where the patient may be struggling or may need additional education and support. |
6 and 12 months post procedure
|
|
Change in Quality of Life
Tidsramme: 12 months post procedure
|
Change in quality of life, as assessed by 36-Item Short Form Health Survey (SF-36) domain scores and Physical and Mental Component Summaries (PCS and MCS), from baseline to 1-year; Higher scores indicate a better, higher quality of life and fewer health-related limitations. |
12 months post procedure
|
|
Adverse Events
Tidsramme: Through study completion, 12 months post procedure
|
Adverse events associated with study procedure and/or study device |
Through study completion, 12 months post procedure
|
Samarbejdspartnere og efterforskere
Sponsor
Efterforskere
- Ledende efterforsker: Shailendra Singh, MD, West Virginia University
- Ledende efterforsker: Ildiko Lingvay, MD, UT Southwestern
Datoer for undersøgelser
Studer store datoer
Studiestart (Anslået)
Primær færdiggørelse (Anslået)
Studieafslutning (Anslået)
Datoer for studieregistrering
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først opslået (Faktiske)
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Yderligere relevante MeSH-vilkår
Andre undersøgelses-id-numre
- E7233
Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter
Studerer et amerikansk FDA-reguleret lægemiddelprodukt
Studerer et amerikansk FDA-reguleret enhedsprodukt
produkt fremstillet i og eksporteret fra U.S.A.
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .